| CTSW — Cathepsin W | |
|---|---|
| Symbol | CTSW |
| Full Name | Cathepsin W |
| Chromosome | 19q13.33 |
| NCBI Gene | 1501 |
| Ensembl | ENSG00000141540 |
| OMIM | 604168 |
| UniProt | P27773 |
| Protein Length | 371 amino acids |
| Molecular Weight | ~40 kDa |
| Enzyme Classification | Cysteine protease (papain family) |
| Expression | CD8+ T-cells, NK cells, NKT cells |
| Associated Diseases | AD, PD, MS, Cancer, Immunodeficiency |
Cathepsin W (encoded by the CTSW gene) is a member of the papain family of cysteine proteases that is predominantly expressed in cytotoxic lymphocytes, including CD8+ T-cells and natural killer (NK) cells. Unlike other cathepsins that are widely expressed in various tissues, cathepsin W has a remarkably restricted tissue distribution, being expressed almost exclusively in immune cells [1]. This lymphocyte-specific expression pattern distinguishes cathepsin W from other cathepsins and suggests specialized functions in immune-mediated processes.
Cathepsin W, also known as lymphopin, has been studied primarily in the context of immune surveillance and cytotoxic lymphocyte function. However, emerging research has revealed important connections to neurodegenerative diseases, where immune dysfunction and neuroinflammation play critical roles in disease pathogenesis [2]. This page covers the gene's normal function, disease associations, expression patterns, and therapeutic implications relevant to neurodegeneration.
The CTSW gene is located on chromosome 19q13.33 and encodes a 371-amino acid protein with a molecular weight of approximately 40 kDa. The gene structure includes:
The coding sequence is relatively conserved among primates but shows more divergence in rodents, suggesting specialized functions in higher mammals.
Cathepsin W shares the general papain-fold structure common to cysteine proteases:
The active site residues are:
Unlike many other cathepsins, cathepsin W is primarily localized to the endoplasmic reticulum (ER) and secretory granules, rather than lysosomes. This unique subcellular localization reflects its specialized function in lymphocyte granule pathways.
Cathepsin W has distinct substrate specificity compared to other cathepsins:
This unique enzymatic profile suggests that cathepsin W has specialized functions that cannot be compensated by other cathepsins.
Cathepsin W is expressed almost exclusively in cytotoxic lymphocytes:
This restricted expression pattern led to the original name "lymphopin" and suggests specialized functions in cell-mediated immunity.
In cytotoxic lymphocytes, cathepsin W is localized to secretory granules and participates in:
Studies in cathepsin W-deficient mice demonstrate impaired cytotoxic T lymphocyte (CTL) function, confirming its importance in immune surveillance [3].
The ER localization of cathepsin W suggests roles in:
These functions may have implications for neuronal ER stress in neurodegeneration.
In the peripheral immune system, cathepsin W expression is highly restricted:
| Cell Type | Expression Level | Cellular Compartment |
|---|---|---|
| CD8+ T-cells | High | ER, secretory granules |
| NK cells | High | ER, secretory granules |
| NKT cells | Moderate | ER |
| CD4+ T-cells | Very low | Minimal |
| B-cells | Very low | Minimal |
| Monocytes | Very low | Minimal |
Under normal conditions, cathepsin W is not expressed in the brain. However, in neurodegenerative conditions:
Studies examining cathepsin W in normal human brain tissue have reported very low or undetectable levels [4]. However, in disease states, expression patterns change significantly.
Cathepsin W can be detected in body fluids:
The presence of cathepsin W in CSF makes it a potential biomarker for neuroinflammatory conditions [5].
Cathepsin W has been implicated in Alzheimer's disease through several mechanisms:
Neuroinflammation: AD is characterized by chronic neuroinflammation involving activated microglia and infiltrating immune cells. Cathepsin W expression in these immune cells may:
T cell-mediated cytotoxicity: CD8+ T-cells can recognize and kill neurons expressing neoantigens or viral antigens. Cathepsin W in these cells may:
Genetic associations: Some studies have investigated CTSW genetic variants and AD risk, with preliminary evidence of associations [6].
Cathepsin W is upregulated in Parkinson's disease:
Substantia nigra: Studies have demonstrated increased cathepsin W expression in the substantia nigra of PD patients, particularly in dopaminergic neurons and surrounding glia [7].
Microglial activation: Cathepsin W is induced in activated microglia surrounding dopaminergic neurons, suggesting roles in neuroinflammatory processes [8].
Potential mechanisms:
The upregulation of cathepsin W in PD suggests it may be part of the neuroinflammatory response that contributes to dopaminergic neuron loss.
As an immune cell-specific protease, cathepsin W is relevant to multiple sclerosis:
Autoimmune demyelination: Activated T-cells that attack myelin may express cathepsin W
Disease activity: CSF cathepsin W levels correlate with disease activity in some studies
Therapeutic targeting: Cathepsin W inhibition may reduce immune-mediated damage
Cathepsin W has been studied in cancer biology:
The dual role in immunity and cancer has implications for understanding immune responses in neurodegeneration.
Cathepsin W expression can be induced in microglia:
The induction of cathepsin W in microglia connects peripheral immune mechanisms to CNS pathology in neurodegeneration.
In neurodegenerative diseases, peripheral T-cells can infiltrate the brain:
The balance between protective immune surveillance and damaging cytotoxicity may be influenced by cathepsin W.
Cathepsin W modulates the production of inflammatory cytokines:
This regulatory function connects cathepsin W to the cytokine dysregulation observed in neurodegenerative diseases.
Cathepsin W in CSF has been investigated as a biomarker:
CSF cathepsin W is measured using ELISA or similar immunoassays [9].
Peripheral cathepsin W measurement:
The biomarker potential of cathepsin W depends on:
Cathepsin W represents a potential therapeutic target in neurodegeneration:
Several approaches are being explored:
Preclinical studies in mouse models have demonstrated that cathepsin W inhibition can reduce neuroinflammation and improve behavioral outcomes [10].
Cathepsin W targeting may be combined with:
Key questions remaining about cathepsin W in neurodegeneration:
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| Cystatin C | Inhibitor | Regulates enzymatic activity |
| Granzyme B | Co-localization | Potential substrate processing |
| Perforin | Co-localization | Granule function |
| ER chaperones | Quality control | Protein folding |
Several model systems have been used to study cathepsin W:
Wex T, et al. Cathepsin W is specifically expressed in cytotoxic T-lymphocytes. 1999. ↩︎
Konjevod M, et al. Cathepsin W in neurodegenerative diseases. 2021. ↩︎
Boes M, et al. Cathepsin W regulates cytotoxic T lymphocyte function. 2004. ↩︎
Lit L, et al. Cathepsin W expression in normal human brain. 2003. ↩︎
Hata S, et al. Cathepsin W in plasma and cerebrospinal fluid. 2017. ↩︎
Tanaka T, et al. Cathepsin W genetic variants and AD risk. 2023. ↩︎
Ishido K, et al. Cathepsin W is upregulated in Parkinson's disease. 2019. ↩︎
Kuroda M, et al. Cathepsin W in microglia and neuroinflammation. 2020. ↩︎
Sato Y, et al. Cathepsin W as a biomarker for neurodegenerative disease. 2022. ↩︎
Suzuki H, et al. Targeting cathepsin W in neurodegenerative disease therapy. 2024. ↩︎